Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
At 1 day after SCI, accumulation of APP and A, the loss of the cytoskeletal proteins such as microtubule associated protein-2 (MAP-2), and axonal demyelination have been found both within and away from injury epicenter (Li et al., 2014), which causes an accumulation of APP, other axonal transport proteins, intracellular components such as lysosomes, neurotrophin, mitochondria and synaptophysin-carrying vesicles
Future research should focus on large-scale, well-controlled randomized trials with standardized dosing protocols, clearly defined deficiency thresholds, and long-term follow-up to strengthen the evidence base and guide clinical practice
Begin with the fundamentals before exploring individual peptide profiles
Oral or troche dose: Determined at APRN intake based on your GI indication and treatment goal Troche format: Held sublingually for 60 to 90 seconds before swallowing for improved absorption Best use case: GI inflammation, IBS, gut lining repair, Crohns management, systemic anti-inflammatory support Not optimal for: Localized tendon, joint, or muscle injury where injection near the site is more targeted Injury vs Gut Protocol: See What Dosing Looks Like for Your Use Case BPC-157 dosage differs by indication
